Progesterone Cream or Oral Progesterone in Menopause: What Matters Most?

Progesterone is often discussed in menopause care as if the form barely matters. Cream, capsule, tablet, same idea, just different packaging. That sounds convenient, but it is not how hormone therapy actually works.

Progesterone cream, oral micronized progesterone, and dydrogesterone are not interchangeable versions of one thing. They differ in structure, absorption, side effects, and most importantly, in how reliably they protect the endometrium when estrogen is part of the plan.

That matters because menopause therapy is not only about easing symptoms. It is also about choosing a regimen that fits the uterus, the estrogen being used, and the real clinical goal.

Why the route matters more than people think

For women who still have a uterus and use estrogen therapy, progesterone or another progestogen is usually needed to protect the endometrium. That is the practical question behind this entire topic. The issue is not which option feels more natural or sounds more modern. The issue is whether the chosen form can do the job it is supposed to do.

Some forms have better evidence for endometrial protection. Some may help with sleep. Some feel easier to tolerate. Those advantages do not automatically travel together, which is why blanket advice tends to fall apart on contact with real patients.

Oral micronized progesterone has the strongest case for first-line use

Micronized progesterone is bioidentical progesterone, meaning the molecule matches the hormone produced by the body. In menopause medicine, that is one reason it is often treated as the default first-line option when estrogen is used and the uterus is still present.

What the evidence actually supports

The KEEPS study helped show that oral micronized progesterone, used in an appropriate cyclic regimen with estrogen, can provide reliable endometrial protection. That is not a cosmetic detail. It is one of the main reasons clinicians keep returning to it.

It may also help with sleep. Oral progesterone forms neuroactive metabolites that reach the central nervous system, and that likely explains why some women notice better sleep quality on it. A 2021 meta-analysis supported that benefit.

Its drawbacks are real too

Oral micronized progesterone can make some women sleepy or dizzy, and that is not always welcome. It also goes through first-pass liver metabolism. For some patients that is acceptable, sometimes even useful if the dose is taken at night. For others it is a reason to look more carefully at tolerability.

Progesterone cream sounds simpler than it is

Transdermal progesterone, whether in a cream or gel, sounds appealing for obvious reasons. It is easy to use, skips first-pass liver metabolism, and often feels gentler than taking a capsule. That is exactly why it gets framed as an easy substitute.

The problem is that convenience and endometrial protection are not the same outcome.

Where the main limitation shows up

Systematic review data and guidance from the British Menopause Society have been fairly clear here: transdermal progesterone has not been shown to provide adequate endometrial protection when used with estrogen therapy. Hormone can be measurable in tissues and still not provide enough protection where it matters most.

That gap is clinically important. Feeling some benefit from a cream does not automatically mean the endometrium is properly protected.

Dydrogesterone is a separate option, not the same hormone in another shape

Dydrogesterone often gets grouped into the same conversation, but it should not be treated as identical to progesterone. It is a synthetic progestogen, not progesterone itself.

That does not make it a bad option. It is well studied in gynecology and often causes less sedation than oral micronized progesterone. But it is still a different molecule with a different clinical profile.

Why that distinction matters

Differences in molecule mean differences in action. Effects on the breast, blood vessels, and overall tolerability may not match what is seen with micronized progesterone. Ongoing research, including the PROBES study, is looking at those differences more closely. For now, the practical point is simple: dydrogesterone is its own choice, not a drop-in replacement for bioidentical progesterone.

How the choice is usually made in real practice

Asking which form is better in the abstract usually leads nowhere useful. The better question is which form fits the actual treatment goal.

If the priority is endometrial protection in a woman with a uterus who is taking estrogen, oral micronized progesterone has stronger support than transdermal cream. If sedation is the main problem, the conversation changes. If the estrogen regimen is different, or the endometrium already needs closer monitoring, the answer may change again.

That is why good menopause care is rarely about slogans such as natural, easier, or safer. It is about matching the molecule and route to the job.

The bottom line

If someone tells you it does not matter how progesterone is taken, that is too simplistic. Route matters. Molecule matters. Evidence matters.

Progesterone cream may come up in treatment discussions, but it should not be assumed to protect the endometrium during estrogen therapy. Oral micronized progesterone remains the more evidence-based first choice when that protection is needed. Dydrogesterone also has a place, but as a different agent with its own rationale.

This article is for educational purposes only and does not replace individual medical advice. Hormone therapy should be chosen with a qualified clinician and tailored to the patient’s specific situation.